磁共振/超声融合活检判定局灶治疗资格
研究纳入454例经多参数磁共振靶向活检证实前列腺癌的男性,其中64例接受根治性前列腺切除术并与全标本病理对照。融合活检判定局灶治疗资格的敏感度为80.0%、特异度为73.5%、准确率为75.0%;175例(38.5%)符合局灶治疗资格。作者认为需改进筛选标准以可靠判定资格。
要点
- 454例中175例(38.5%)符合局灶治疗资格。
- 融合活检判定资格的敏感度80.0%、特异度73.5%、准确率75.0%。
- 仅靶向针敏感度73.3%、特异度47.9%、准确率54.7%。
核心结论
- 使用中危资格标准,超过三分之一经多参数磁共振靶向活检证实病灶的男性符合局灶治疗资格。
- 融合活检判定的资格与全标本组织学在75%的病例中一致。
- 需要改进筛选标准以可靠判定局灶治疗资格。
研究设计与样本
- 研究从2010年至2016年经多参数磁共振感兴趣区靶向活检证实前列腺癌的454例男性中选取受试者。
- 局灶治疗资格限定为感兴趣区最高Gleason评分4+3,伴或不伴其他低危前列腺癌病灶(Gleason评分3+3且小于4 mm)。
- 不符合NCCN中危标准的男性被归类为不适合局灶治疗。
- 454例中64例接受根治性前列腺切除术,并将活检结果与最终病理结果进行比较。
主要发现
- 454例活检证实感兴趣区的男性中175例(38.5%)符合局灶治疗资格。
- 融合活检(联合靶向与模板活检)判定局灶治疗资格的敏感度为80.0%(12/15例),特异度为73.5%(36/49),准确率为75.0%(48/64)。
- 仅靶向针的敏感度为73.3%(11/15例),特异度为47.9%(23/48),准确率为54.7%(35/64)。
- 在活检与全标本组织学不一致的13例中,Gleason评分不同者4例,跨中线延伸不同者9例。
关键数值与推荐
- 局灶治疗资格:感兴趣区最高Gleason评分4+3,伴或不伴其他低危病灶(Gleason评分3+3且小于4 mm)。
- 不符合NCCN中危标准者归类为不适合局灶治疗。
- 融合活检判定资格的敏感度80.0%(12/15例)、特异度73.5%(36/49)、准确率75.0%(48/64)。
- 仅靶向针的敏感度73.3%(11/15例)、特异度47.9%(23/48)、准确率54.7%(35/64)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要改进筛选标准以可靠判定局灶治疗资格。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed focal therapy eligibility in men who underwent multiparametric magnetic resonance imaging and targeted biopsy with correlation to whole mount histology after radical prostatectomy. MATERIALS AND METHODS: Subjects were selected from among the 454 men in whom targeted biopsy proven prostate cancer was derived from regions of interest on multiparametric magnetic resonance imaging from 2010 to 2016. Focal therapy eligibility was limited to a maximum Gleason score of 4 + 3 in regions of interest with or without other foci of low risk prostate cancer (Gleason score 3 + 3 and less than 4 mm). Men who did not meet NCCN® intermediate risk criteria were classified as ineligible for focal therapy. Of the 454 men 64 underwent radical prostatectomy and biopsy findings were compared to final pathology findings. RESULTS: Of the 454 men with a biopsy proven region of interest 175 (38.5%) were eligible for focal therapy. Fusion biopsy, which combined targeted and template biopsy, had 80.0% sensitivity (12 of 15 cases), 73.5% specificity (36 of 49) and 75.0% accuracy (48 of 64) for focal therapy eligibility. Targeted cores alone yielded 73.3% sensitivity (11 of 15 cases), 47.9% specificity (23 of 48) and 54.7% accuracy (35 of 64). Gleason score and extension across the midline differed in 4 and 9, respectively, of the 13 cases that showed discordant biopsy and whole mount histology. CONCLUSIONS: Using intermediate risk eligibility criteria more than a third of men with a targeted biopsy proven lesion identified on multiparametric magnetic resonance imaging would have been eligible for focal therapy. Eligibility determined by fusion biopsy was concordant with whole mount histology in 75% of cases. Improved selection criteria are needed to reliably determine focal therapy eligibility.
引用
- Nassiri N, Chang E, Lieu P, et al. Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. J Urol. 2017. PMID: 28830754. doi:10.1016/j.juro.2017.08.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。